Latest news, events and publications from EPICS Therapeutics

Cresset Discovery accelerates optimization of METTL3 inhibitor

Cresset Discovery has delivered a highly efficient digital workflow combining their molecular modeling expertise with Cresset technology to accelerate discovery, design and optimization of a METTL3 inhibitor. Working with Epics Therapeutics, the workflow combines scaffold hopping, in silico design and prioritization together with Epic’s medicinal chemistry team to drive efficient hit discovery and optimization, enabling progression towards a drug development candidate.

EPICS To Present Preclinical Data on METTL3 Inhibitor EP102 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22 - 26, 2025.. Hynes Convention Center Boston, Massachusetts

EPICS’s In Silico Modeling Partner Publishes Study Featuring EP652 in Journal of Medicinal Chemistry

EPICS to Attend BIO-Europe 2025 in Vienna

November 3–5, 2025. Vienna Congress and Convention Center, Vienna, Austria.

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22 - 26, 2025. Hynes Convention Center Boston, Massachusetts.

EPICS at the BIO Investment Convention 2025 in Charleroi

October 16, 2025. Palais des expositions de Charleroi, Charleroi, Belgium.
​

​

EPICS Therapeutics Announces First Cohort Dosed with EP102 in First-In-Patient Oncology Trial and Securement of Additional Financing

Amelioration of Central Nervous System Autoimmunity Through FFAR2 Agonism Is Associated With Changes in Gut Microbiota

EPICS Therapeutics publishes the medicinal chemistry and efficacy of its proprietary METTL3 inhibitors in the Journal of Medicinal Chemistry

EPICS Therapeutics Appoints Graeme Fraser PhD, Chief Executive Officer and Raises €12M in Series A Preferred Financing to Advance its Oncology Pipeline

Increased regulatory activity of intestinal innate lymphoid cells type 3 (ILC3) prevents experimental autoimmune encephalomyelitis severity

EP102, a METTL3 inhibitor that demonstrates strong stand-alone in vivo efficacy and synergistic activity with venetoclax for the treatment of acute myeloid leukemia will be presenting at the ASH 2023 conference